Matinas Biopharma Holdings, Inc. (MTNB) earnings
MTNB earnings moved a median of -1.88% by the close. Quarterly and annual MTNB reports and results, each read against the price at its own news timestamp. Back to the MTNB overview →
19 measured MTNB earnings events.
Where these MTNB earnings landedvs 19 measured MTNB earnings reactions
| Middle 50% of MTNB earnings reactions | -3.62% to +0.92% |
|---|---|
| Median reaction (to close) | -1.88% |
| Measured reactions | 19 |
Point-in-time · zero look-ahead
Half of the 19 MTNB earnings events with a measured close landed between -3.62% and +0.92%; 26% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Matinas BioPharma Holdin For: Jun 30 | SEC filing · Form 10-Q | -2.26% | -1.97% | |
| Form 10-Q Matinas BioPharma Holdin For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +4.95% | |
| Form 10-K Matinas BioPharma Holdin For: Dec 31 | SEC filing · Form 10-K | +0.00% | +0.00% | |
| Form 10-Q Matinas BioPharma Holdin For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -6.25% | |
| Form 10-Q Matinas BioPharma Holdin For: Jun 30 | SEC filing · Form 10-Q | +4.40% | +48.43% | |
| Form 10-Q Matinas BioPharma Holdin For: Mar 31 | SEC filing · Form 10-Q | -0.85% | +21.91% | |
| Form 10-K Matinas BioPharma Holdin For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.88% | |
| Form NT 10-K Matinas BioPharma Holdin For: Dec 31 | SEC filing · Form NT | +5.77% | +9.62% | |
| Form 10-Q Matinas BioPharma Holdin For: Sep 30 | SEC filing · Form 10-Q | -9.31% | -5.68% | |
| Form 10-Q Matinas BioPharma Holdin For: Jun 30 | SEC filing · Form 10-Q | -3.49% | -2.98% | |
| Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | -3.49% | -2.98% | |
| Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 | Press release | -1.63% | -4.00% | |
| Form 10-Q Matinas BioPharma Holdin For: Mar 31 | SEC filing · Form 10-Q | +0.06% | -0.62% | |
| Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update | Press release | +0.06% | -0.62% | |
| Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024 | Press release | +0.72% | +1.83% | |
| Form 10-K Matinas BioPharma Holdin For: Dec 31 | SEC filing · Form 10-K | +0.36% | -3.25% | |
| Form 10-Q Matinas BioPharma Holdin For: Sep 30 | SEC filing · Form 10-Q | +2.15% | -13.15% | |
| Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update | Press release | +2.15% | -13.15% | |
| Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023 | Press release | -1.27% | -1.88% |
Keep exploring
More MTNB: analyst actions → · SEC filings → · MTNB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NIGHTSTAR THERAPEUTICS PLC AMERICAN DEPOSITARY SHA (NITE) | 164 | -0.04% | 28% |
| NanoViricides, Inc. (NNVC) | 164 | +0.01% | 52% |
| NanoVibronix, Inc. (NAOV) | 161 | -0.40% | 39% |
| Zomedica Corp. Common Shares (ZOM) | 161 | +0.08% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.